Clinical Policy: Bortezomib for treatment in immune Thrombotic Thrombocytopenic Purpura (TTP)

Overview

Bortezomibi is a proteasome inhibitor that is currently licenced for the treatment of multiple myeloma and mantle cell lymphoma. For those patients who are intolerant or refractory to rituximab, bortezomib was proposed as an alternative treatment option in those with immune thrombotic thrombocytopenic purpura (TTP).

This policy proposition is that bortezomib is not recommended to be available as a routine commissioning option for the treatment of acute immune TTP or prevention of acute TTP relapse due to lack of sufficient evidence identified.

Information about other treatments that are commissioned for the same population can be found on our specialised blood disorders page. 

This public consultation will run for 30 days from 13 May to 12 June 2024.

At the end of the consultation period, all feedback will be considered before the interim clinical policy is published.

Supporting documentation

• Clinical commissioning policy proposition
• Equality and health inequalities impact assessment
• Engagement report
• NHS England evidence review: bortezomib for acute immune thrombotic thrombocytopenic purpura
• NHS England evidence review: bortezomib for prevention of acute immune thrombotic thrombocytopenic purpura